Biotech Startups

Startuplab.01 is a deep tech hub in Chile offering specialized laboratories (nearly 1,000m²) and collaborative workspaces for early-stage scientific and technological startups from TRL 4-5. It provides support and acceleration programs to help startups in fields such as biotechnology, agrifood, energy, and mining validate, pilot, and scale their technologies alongside industry.

1 investor

StataDx is developing a point-of-care diagnostic platform for neurology that measures multiple blood biomarkers (such as Neurofilament-light, pTau-217, GFAP, S100b, and UCH-L1) from a fingerprick whole blood sample. The system uses multiplexed cartridges with mobile and cloud connectivity for biomarker-guided disease management in clinics or at patients' homes.

1 investor

Stayble Therapeutics is a clinical-stage pharmaceutical company developing an injection-based treatment for disc herniation. The company is currently conducting phase 1b clinical trials for its therapeutic candidate.

1 investor

Steel Therapeutics is a pharmaceutical company that develops a pipeline of drug candidates and manages the associated regulatory, clinical, and product delivery work. It draws on pharmacy compounding and clinical trial expertise to bring medications to market.

1 investor

Stelara is a prescription biologic medication presented as a treatment option for adults and children with conditions including psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis.

1 investor

StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties. It supplies cells and cell expansion tools for stem cell research and regenerative medicine applications.

1 investor

StemBond makes SENCE, a range of cell culture well plates (6 to 96 wells), coverslips and inserts pre-coated with a proprietary animal-free hydrogel tuned to tissue-relevant stiffnesses. The synthetic, xeno-free surfaces are sold as reorderable consumables to researchers and biotechs to reduce variability and improve reproducibility in standard cell culture workflows.

1 investor

StemCyte is a cord blood banking and regenerative therapeutics company offering private and public cord blood and cord tissue collection, processing, and cryopreservation for expectant families. It operates an FDA-licensed cGMP facility, supplies cord blood units to transplant centers worldwide, and develops cord blood-derived therapies.

1 investor

StemInov is a biotech developing WhartSep, an off-the-shelf stem cell therapy derived from umbilical cord (Wharton's jelly) cells with three complementary actions to treat severe pneumonia and sepsis. The company targets immune disorders and tissue repair as unmet medical needs.

1 investor

Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer. It is part of the Menarini Group, an international pharmaceutical and diagnostics company.

1 investor

Stemmatters is a Contract Development and Manufacturing Organisation (CDMO) focused on regenerative medicine, providing product and process development plus cGMP production and clinical translation of medicinal products. It supports customers with CMC activities, regulatory dossier preparation, and clinical batch release for investigational and advanced therapy medicinal products.

1 investor

Stemnovate provides an integrated platform combining multiomics data, cell reprogramming technology, and mechanistic functional studies to accelerate drug discovery and clinical translation for rare diseases, neurodegenerative conditions, and other therapeutic areas across human and animal health. The company operates cellular biobanks, develops microphysiological systems for in vitro testing, and partners with pharmaceutical and academic institutions to reduce reliance on animal testing while enabling precision medicine research.

1 investor

Stem Pharm develops therapeutics using stem cell technology for disease treatment and drug discovery. The company serves pharmaceutical and biotech partners seeking advanced cell-based approaches to translational drug development.

1 investor

StemSight develops stem cell-based therapies to restore sight, focusing on treatments for corneal conditions such as limbal stem cell deficiency using pluripotent stem cells. The company, spun out of the Skottman Lab's Eye Regeneration Group, targets patients with untreatable eye diseases in collaboration with cornea clinicians.

1 investor

Sterilex develops sanitation, disinfection, and microbial control products for use in food processing facilities, water systems, and animal environments.

1 investor

Stiefel is a biopharmaceutical company that discovers, develops and delivers medicines and vaccines. Its R&D focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

1 investor

StimLabs develops regenerative medicine products, including its Corplex P device, used by physicians for wound healing and complex clinical cases. The company markets a portfolio of regenerative technologies for patient care.

1 investor

StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.

1 investor

1 investor

Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.

1 investor

StrainTrace develops a targeted molecular assay for rapid Listeria strain typing, generating a binary strain fingerprint from genetic markers without producing genome sequence data. It serves food safety testing labs and food manufacturers, letting them track strain recurrence over time to distinguish persistent harborage sites from transient contamination.

1 investor

Strand Life Sciences enables precision medicine globally through bioinformatics, genomics analysis, and clinical research services. The company develops AI-driven platforms and analytical tools for omics data processing, including automated oncology panel reporting and digital histopathology infrastructure.

1 investor

Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors. The company targets patients with advanced solid tumors where current treatment options are limited.

1 investor

Dennis Gong is a PhD candidate in Medical Engineering and Medical Physics at Harvard Medical School and MIT, conducting research on therapeutic resistance and recurrence in pancreatic cancer at MGH Center for Cancer Research and the Broad Institute. His stated goal is to build biotech companies and develop transformative new medicines.

1 investor